Showing 117 of 117on this page. Filters & sort apply to loaded results; URL updates for sharing.117 of 117 on this page
记住所有FDA生物药 | 靶向CD20 x CD3双抗 | Epcoritamab | 弥漫性大B细胞淋巴瘤(DLBCL) - 知乎
Full article: Epcoritamab in B-cell malignancies: current status and ...
Bispecific Antibody Research Update: Epcoritamab Receives FDA Priority ...
Lymphoma Australia Epcoritamab - New Treatment for DLBCL
Epcoritamab (TEPKINLY®) [Acthera]
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is ...
(PDF) Epcoritamab induces potent anti-tumor activity against malignant ...
Full article: Combinability of epcoritamab CD20-targeting T-cell ...
Epcoritamab induces potent anti-tumor activity against malignant B ...
Epcoritamab (GEN3013) | Anti-CD3/CD20 Antibody | MedChemExpress
SUBCUTANEOUS EPCORITAMAB (GEN3013; CD3XCD20) IN PATIENTS WITH.... EHA ...
Epcoritamab (Epkinly), a novel bispecific antibody to target cancer ...
Epcoritamab (GEN3013，艾可瑞妥单抗) - 仅供科研 | 抗CD3/CD20抗体 | MCE
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy ...
Lower T-cell activation by epcoritamab in presence of tumor cells with ...
Dose escalation of subcutaneous epcoritamab in patients with relapsed ...
Epcoritamab Bispecific antibody for large B-cell lymphoma Stock Photo ...
Epcoritamab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
Epcoritamab Combo Shows Benefits in Phase 3 Follicular Lymphoma, Moves ...
Epcoritamab Granted Priority Review for Relapsed/Refractory Large B ...
The Bispecific Antibody Epcoritamab Produces Responses in Lymphoma ...
AbbVie, Genmab’s Bispecific Antibody Epcoritamab Achieves High Rate of ...
Preliminary Analysis of Data Evaluating Investigational Epcoritamab ...
Epcoritamab mediates comparable levels of cytotoxicity in various B-NHL ...
Epcoritamab monotherapy in patients with relapsed or refractory ...
FDA批准第2款CD3/CD20双抗：艾伯维/Genmab的Epcoritamab Armstrong 2023年5月19日，艾伯维 ...
The wonders of the T-cell: bispecific antibodies in diffuse large B ...
Bispecific antibodies in follicular lymphoma | Haematologica
The Role of Bispecific Antibodies in Non-Hodgkin’s Lymphoma: From ...
CD20 X CD3双特异抗体格局 近日， Genmab 和艾伯维宣布其靶向CD20xCD3的双特异抗体epcoritamab（GEN3013 ...
$康诺亚-B(02162)$ 创新药周报20230521：Epcoritamab获批，关注CD3×CD20双抗进展原创 ... - 雪球
Mechanism of Action - EPKINLY® (epcoritamab-bysp) HCP
Full article: Trial watch: bispecific antibodies for the treatment of ...
Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging ...
Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging ...
Bispecific Antibodies for Lymphoid Malignancy Treatment
Rapid Generation of Bispecific Antibodies for High-Throughput Screening ...
艾可瑞妥单抗(Epcoritamab) - 药物靶点：CD20 x CD3_在研适应症：大B细胞淋巴瘤，复发性 3b 级滤泡性淋巴瘤，纵隔大b ...
RxTROSPECT — FDA Approve EPKINLY™ (epcoritamab-bysp) as the First ...
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic ...
艾伯维重磅新型CD3/CD20双抗Epkinly（epcoritamab）获美FDA加速批准！_细胞_患者_治疗
新面孔！缓解率61%！新型CD3/CD20双抗Epcoritamab获得美国FDA加速批准_可愈有道
ALL和NHL领域，临床开发中的双特异抗体__中国医疗
2024年6月26日FDA加速批准CD3/CD20双特异性抗体疗法Epcoritamab-bysp(艾可瑞妥单抗、Epkinly)用于治疗治疗 ...
Epcoritamab有效率88%，双抗治疗肿瘤时代或将到来|剂量|细胞|其中|方面|淋巴瘤|-健康界
创新“血与蜜之地”：巨头先行，CD20/CD3双抗突破在望 - 知乎
Bispecific Antibody Expands Reach to Follicular Lymphoma | Research | AACR
Bispecific Antibodies: Design, Development & Therapeutic Potential ...
艾伯维重磅新型CD3/CD20双抗Epkinly（epcoritamab）获美FDA加速批准！-印塔健康官网
【柳叶刀血液学】CD3/CD20双抗Epcoritamab治疗R/R FL的2期研究结果-MedSci.cn
(Epcoritamab) - 药物靶点：CD20 x CD3_在研适应症：纵隔大b细胞淋巴瘤，复发性滤泡性淋巴瘤，难治性滤泡性淋巴瘤_专利 ...
Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse ...
FDA批准第2款CD3/CD20双抗：艾伯维/Genmab的Epcoritamab医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
RxTROSPECT — European approval for AbbVie's TEPKINLY® (epcoritamab) for ...
Xia & He Publishing
L’Epcoritamab - Un nouvel anticorps dans le lymphome B diffus à grandes ...
大B细胞淋巴瘤(LBCL)新药！CD3xCD20双特异性抗体epcoritamab在美欧进入审查：总缓解率63%！ - 知乎
Anti-CD20/CD3-Epcoritamab Antibody, 68185-H001 | Sino Biological
Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific ...
Antibody Function Ncbi at Crystal Molden blog
创新药周报：Epcoritamab获批，关注CD3×CD20双抗研发进展
CD20/CD3双抗联合R2方案治疗初治滤泡性淋巴瘤，总缓解率高达95% - 知乎
FDA approves bispecific antibody EPKINLY™ (epcoritamab-bysp) - The ...
Epkinly (Epcoritamab) Approved as First Bispecific Antibody for Most ...
Scottish Medicines Consortium approves first subcutaneous bispecific ...
CD3/CD20 (Epcoritamab) Antibody - Azide and BSA Free (NBP3-44563 ...
FDA Announces AI Strategy with First AI-Assisted Scientific Pilot for ...
3.75万美元/月！又一款CD20xCD3双抗获批上市，治疗大B细胞淋巴瘤_摩熵医药(原药融云)
Follicular lymphoma: study results with bispecific antibodies and BTK ...
Epkinly (epcoritamab) dosing, indications, interactions, adverse ...
CD20/CD3双特异性抗体Epcoritamab治疗复发/难治性LBCL/DLBCL向FDA提交上市申请 - 知乎
T-cell-engaging bispecific antibodies in cancer - The Lancet
FDA Approves Epcoritamab-Based Regimen in Follicular Lymphoma ...
Therapeutic potential of CD20 x CD3 bispecific antibodies
The Landscape of Bispecific and Multispecific Antibodies
A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific ...
00889-8/asset/5ffb5e54-82c5-4a56-8a24-bf468ed6b7dc/main.assets/gr4_lrg.jpg)
00889-8/asset/f8ef32d8-e2f9-4baf-b793-4a1ee10fea30/main.assets/gr2_lrg.jpg)
00166-2/asset/0e50bf90-ddfa-4027-8d09-06471fb07aa7/main.assets/gr1_lrg.jpg)
.png?format=1000w)
.png)
